Compare OWLS & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLS | EVMN |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.9M | 474.7M |
| IPO Year | 2024 | 2025 |
| Metric | OWLS | EVMN |
|---|---|---|
| Price | $5.46 | $9.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $11.00 | ★ $43.88 |
| AVG Volume (30 Days) | 26.8K | ★ 562.8K |
| Earning Date | 04-29-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $375.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $4.77 | $10.30 |
| 52 Week High | $29.00 | $33.20 |
| Indicator | OWLS | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 29.27 |
| Support Level | $5.25 | N/A |
| Resistance Level | $5.66 | $13.35 |
| Average True Range (ATR) | 0.22 | 0.68 |
| MACD | 0.02 | -0.30 |
| Stochastic Oscillator | 87.49 | 1.67 |
OBOOK Holdings Inc operate as a blockchain-powered technology company. It provides solutions across three main business segments: payments, hospitality, and e-commerce, serving businesses and individuals whose commercial activities involve cross-border transactions. The company has five reportable segments: Payment service provides payment solutions to customers, including payment gateway services and payout services; Hospitality-related software services provide the subscription to the OwlNest PMS and the add-on room fee collection services offered to the clients using OwlNest; Hospitality-related platform services that provide an OTA platform and offline platform services offering accommodation services; The E-commerce platform engages in selling products online; and Other services.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.